Hepatitis Monthly

Published by: Kowsar

Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran

Fatemeh Zare 1 , Mohammad Reza Fattahi 1 , * , Masood Sepehrimanesh 1 and Ali Reza Safarpour 1
Authors Information
1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: April 2016, 16 (4); e32654
  • Published Online: March 5, 2016
  • Article Type: Research Article
  • Received: August 24, 2015
  • Revised: February 5, 2016
  • Accepted: February 5, 2016
  • DOI: 10.5812/hepatmon.32654

To Cite: Zare F, Fattahi M R, Sepehrimanesh M, Safarpour A R. Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran, Hepat Mon. 2016 ;16(4):e32654. doi: 10.5812/hepatmon.32654.

Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Brown RJ, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003; 9(11)-3[DOI][PubMed]
  • 2. Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. Hepat Mon. 2008; 8(3): 165-9
  • 3. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997; 26(3): 521-6[DOI][PubMed]
  • 4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8): 556-62[DOI][PubMed]
  • 5. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran; epidemiology, diagnosis, prevention and treatment. Sci J Med Council Islam Republic Iran. 1997; 15: 183-200
  • 6. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of Hepatitis B and C in Patients With Hemophilia: A Single-Centre Descriptive Study. Shiraz E Med J. 2015; 16(7)[DOI]
  • 7. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 8. Gabriella De Carli M, Puro V, Ippolito G. Risk of hepatitis C virus transmission following per-cutaneous exposure in healthcare workers. Infection. 2003; 31(5)
  • 9. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5): 352-8[DOI][PubMed]
  • 10. Alavian SM, Fallahian F, Lankarani KB. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepat Mon. 2008; 8(1): 51-9
  • 11. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998; 53(4): 1022-5[DOI][PubMed]
  • 12. Regev A, Schiff ER. Viral hepatitis. Curr Opin Gastroenterol. 1999; 15(3): 234-9[PubMed]
  • 13. Mirmomen S, Alavian SM. Treatment of HCV infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response. Hepat Mon. 2005; 5(1): 111-3
  • 14. Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon. 2015; 15(2)[DOI][PubMed]
  • 15. Malone DC. Cost-effectiveness analysis of interferon a-2b with ribavirin for chronic hepatitis C infection. Formulary. 2000; 35(8): 681
  • 16. Vrontisi Z, Abrell J, Neuwahl F, Saveyn B, Wagner F. Economic impacts of EU clean air policies assessed in a CGE framework. Environ Sci Policy. 2016; 55: 54-64[DOI]
  • 17. Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat. 2009; 16(1): 53-63[DOI][PubMed]
  • 18. Merat S, Poustchi H. Hepatitis C in Iran. How extensive of a problem is it? Arch Iran Med. 2012; 15(5): 268[PubMed]
  • 19. Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Abedin Dorkoosh F, Keshvari M, et al. Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran. Hepat Mon. 2015; 15(4)[DOI]
  • 20. Ashtari S, Vahedi M, Pourhoseingholi MA, Pourhoseingholi A, Safaee A, Moghimi-Dehkordi B, et al. Estimation of average diagnosis and treatment costs of hepatitis C. Gastroenterol Hepatol Bed Bench. 2012; 5(3): 139-45[PubMed]
  • 21. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6): 2164-70[DOI][PubMed]
  • 22. Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag. 2002; 5(2): 95-107
  • 23. Kavosi Z, Zare F, Jafari A, Fattahi MR. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Middle East J Dig Dis. 2014; 6(3): 156-61[PubMed]
  • 24. Varmaghani M, Arab M, Zeraati H. The most important factors that patient choose public or private hospital. 2008;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader